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in the new DSM-5 version to accommodate a mixed categorical–dimensional concept. The new
classiﬁcation will capture subthreshold non-overlapping symptoms of the opposite pole using a “with
mixed features” speciﬁer to be applied to manic episodes in bipolar disorder I (BD I), hypomanic, and
major depressive episodes experienced in BD I, BD II, bipolar disorder not otherwise speciﬁed, and major
depressive disorder. The revision will have a substantial impact in several ﬁelds: epidemiology, diagnosis,
treatment, research, education, and regulations. The new concept is data-driven and overcomes the
problems derived from the extremely narrow deﬁnition in the DSM-IV-TR. However, it is unclear how
clinicians will deal with the possibility of diagnosing major depression with mixed features and how this
may impact the bipolar–unipolar dichotomy and diagnostic reliability. Clinical trials may also need to
address treatment effects according to the presence or absence of mixed features. The medications that
are effective in treating mixed episodes per the DSM-IV-TR deﬁnition may also be effective in treating
mixed features per the DSM-5, but new studies are needed to demonstrate it.
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-NC-ND license.1. Introduction
Mixed affective states, deﬁned as the coexistence of depressive
and manic symptoms, are complex presentations of manic-
depressive illness that represent a challenge for clinicians at the
diagnosis, classiﬁcation, and pharmacological treatment levels. The
current version of the Diagnostic and Statistical Manual of Mental
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Psychiatric Association, 2000) classiﬁcation system has undergone
a revision process to supplement categorical diagnoses with dimen-
sional approaches, with a “mixed-categorical–dimensional” approach
(Wittchen et al., 2011). In the updated DSM-5 version, to be published
by May 2013, the mixed episode as deﬁned in DSM-IV-TR (juxtaposed
full manic and depressive episodes) will be removed, and subthres-
hold non-overlapping symptoms of the opposite pole will be
captured using a “with mixed features” speciﬁer to be applied to
manic episodes and major depressive episodes (MDEs). We review
here the impact of this new classiﬁcation and the challenges that
clinicians and researchers will face with its use and implementation.2. Mixed states: history of the concept, deﬁnitions,
epidemiology, and clinical characteristics
Following the ﬁrst description of manic-depressive illness as
a single disease with 2 opposite constellations of symptoms by
Aretaeus of Cappadocia (Marneros and Goodwin, 2005), the
simultaneous occurrence of manic and depressive features was
conceptualized by Kraepelin (1899) and Weygandt (1899) at the
end of the 19th century. Kraepelin and Weygandt referred to
them as “mixed states”, and categorized them into 6 different
subtypes based on the replacement of ≥1 of the fundamental
symptoms of mania by ≥1 of the fundamental symptoms of
depression, and vice versa (Marneros and Goodwin, 2005).
Therefore, the deﬁnition inherently supposed a grading from a
“broad deﬁnition”, or mixture of main symptoms of 1 pole with
symptoms of the other pole, to a “narrow deﬁnition”, or the
simultaneous occurrence of the full symptomatology of both a
manic and a depressive episode.
During the evolution of modern psychiatry, the importance of
mixed states was increasingly recognized by psychiatrists, but
Kraepelin's concept of a continuum between manic and depressive
states was not incorporated into major psychiatric diagnostic systems
such as the DSM III, DSM-III-R, DSM-IV, DSM-IV-TR (American
Psychiatric Association, 1980, 1987, 1994, 2000), and the International
Classiﬁcation of Diseases, Tenth Edition (ICD-10) (World Health
Organization, 1992). The current nomenclature is narrow: in DSM-
IV-TR (American Psychiatric Association, 2000), a mixed episode is
deﬁned as the co-occurrence of DSM-IV-TR–deﬁned mania and
depression for ≥1 week in the context of bipolar disorder I (BD I),
and the ICD-10 classiﬁcation (World Health Organization, 1992)
requires that the two sets of symptoms are both prominent for the
greater part of the current episode of illness (for ≥2 weeks), and that
there has been ≥1 past affective episode. These restrictive bidimen-
sional criteria undermine the existence of subsyndromal mixed
states, and obscure the fact that, in clinical practice, the most
prevalent clinical presentation of mixed episodes is the presence of
few concomitant symptoms of the opposite polarity (Akiskal et al.,
1998; Goldberg et al., 2009; Perugi et al., 1997, 2001; Suppes et al.,
2005; Swann et al., 2009).
The need for a reliable deﬁnition of a mixed state has triggered
the development of different criteria that range from intermediate
categorical deﬁnitions to broader dimensional approaches. For exam-
ple, the Vienna criteria (Berner et al., 1983) are based on persisting
changes in individuals′ emotions and drive contradictory to the
mood state and/or emotional resonance; the Cincinnati criteria
(Cassidy and Carroll, 2001; McElroy et al., 1992, 1995) require the
presence of ≥3 associated depressive symptoms to diagnose mixed
mania; and the Pisa-San Diego criteria (Perugi et al., 1997) are based
on the presence of 2 of 5 clinical and temperament characteristics.
Even broader deﬁnitions require only 1 depressive symptom
(Akiskal, 1992) or a temperament opposing a manic state (Duke/ROC criteria) (Cassidy et al., 2000). Finally, it has also been proposed
that the criteria for the diagnosis of a mixed mood episode in the
clinical setting should be based on the presence of 43 nonoverlap-
ping symptoms of the opposite polarity, whereas in research, speciﬁc
cut-offs in symptom scales should be incorporated (e.g., a score ≥10
on the Hamilton Depression Rating Scale for a hypomanic mixed
episode, or a Schedule for Affective Disorders and Schizophrenia
score ≥8 for a depressive mixed episode) (Swann et al., 2013b).
Mixed states are common in the context of BD (Akiskal et al.,
2000), but a direct consequence of the diverse deﬁnitions is that
the reported prevalence rate varies signiﬁcantly between studies.
For mixed manic states, the recognized overall mean global
prevalence is 31% (McElroy et al., 1992), but the prevalence based
on the narrow deﬁnitions of ICD-10 and DSM-III/IV is reported to
be between 6.7% and 28%, and is up to 66% when using broader
deﬁnitions (Cassidy et al., 2008). In a cross-sectional multicenter
study, Vieta and Morralla (2010) reported 9% prevalence accord-
ing to ICD-10 criteria, 13% prevalence according to DSM-IV-TR
criteria, 17% according to Cincinnati criteria, and 23% by clinicians
′ assessment. Predominantly depressive mixed states have been
studied less, but the reported rates also vary, between 20% and
70%, depending on the use of narrow or broad deﬁnitions (Azorin
et al., 2012; Benazzi, 2008; Goldberg et al., 2009).
The prevalence of mixed mania is higher in women, ranging
from 63% to 69% using most deﬁnitions (Cassidy et al., 2008),
whereas the majority of studies agree that there is no sex
difference in the prevalence of mixed depression (Akiskal et al.,
2005; Azorin et al., 2012; Benazzi, 2003; Perugi et al., 2001).
Regarding the age of onset, the majority of studies report that
both mixed mania and mixed depression occur at a younger age
than pure episodes (Azorin et al., 2012; Benazzi, 2008; Cassidy
and Carroll, 2001; Goldberg et al., 2009; Gonzalez-Pinto et al.,
2011; Perugi and Akiskal, 2005; Valenti et al., 2011), although
similar or older ages have also been described (Benazzi, 2008;
Hantouche et al., 2006; Perugi and Akiskal, 2005; Perugi et al.,
2001).
Compared to pure manic episodes, the clinical picture of
mixed mania shows that patients tend to experience more
episodes of illness, with episodes of longer duration (Martin-
Carrasco et al., 2012) and more functional impairment (Rosa
et al., 2009). In addition, they are more likely to have experienced
previous mixed episodes, to relapse, to have lower interepisode
intervals with a higher risk of a future mixed episode, and to have
higher rates of suicide and comorbid conditions such as sub-
stance abuse (Azorin et al., 2009; Baldessarini et al., 2010;
Cassidy et al., 2008; Gonzalez-Pinto et al., 2010; Kessing, 2008;
Valenti et al., 2011). Similar to mixed mania, mixed depressive
patients differ from pure bipolar depressives in that they are
more likely to show a mixed state at the ﬁrst episode; have more
severe episodes of longer duration; have less interepisodic
remission; have higher recurrence rates of depressive or hypo-
manic episodes; have more rapid cycling; have more previous
mixed episodes; and have more incongruent psychotic features,
suicide attempts, and alcohol abuse (Akiskal et al., 2005; Azorin
et al., 2012; Goldberg et al., 2009; Perugi et al., 2001). Thus, the
combination of components of manic and depressive states is
associated with a more severe form of BD with a worse course of
illness and higher rates of comorbid conditions.3. DSM-5, Challenges for mixed states
3.1. Implications for diagnosis
The coding of syndromes and mental disorders based on catego-
rical deﬁned diagnostic criteria in DSM-IV-TR has undoubtedly resulted
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However, as a result, multiple diagnoses have become a rule, with high
rates of cross-sectional co-occurrence of symptoms and lifetime
comorbidity (Wittchen et al., 2011). This is a recognized problem
and has been considered to be associated with a loss of diagnostic
validity (Lecrubier, 2008), raising a debate on nosological considera-
tions. These issues eventually prompted a DSM revision (DSM-5) that
is reoriented to supplement categorical diagnoses with dimensional
approaches in a “mixed-categorical–dimensional” approach (Wittchen
et al., 2011). For BD, the DSM-IV-TR strict categorical deﬁnitions have
been largely criticized for their inability to address subsyndromal
presentations, and the development of a mixed modular approach
including dimensions within the categorical classiﬁcation had pre-
viously been proposed (Vieta and Phillips, 2007). Moreover, although
the co-occurrence of manic and depressive symptoms is frequently
seen in clinical practice, mixed states are characterized by a complex
symptomatologic picture that is difﬁcult to capture with the DSM
combinatorial model. This includes severe anxiety and prolonged
affective instability, the latter probably related to emotional perplexity,
psychotic experiences, and grossly disorganized behavior (Perugi and
Akiskal, 2005). Psychotic features, for instance, correlate with the
degree to which affective symptoms are mixed (Swann et al., 2009),
but many cases of severe psychotic mixed states are misdiagnosed and
mistreated as schizophrenia (Lake, 2008).
In DSM-5, mood episodes will be deﬁned as being manic,
major depressive, or hypomanic, and the mixed episode as
deﬁned in DSM-IV-TR (juxtaposed full manic and depressive
episodes) will be removed. The updated DSM-5 will capture
subthreshold nonoverlapping symptoms of the opposite pole
using a “with mixed features” speciﬁer to be applied to manic
episodes in BD I; hypomanic episodes in BD I and II; and MDEs
experienced in BD I, BD II, BD not otherwise speciﬁed (BD-NOS),
and major depressive disorder (MDD) (Table 1). This decision
arises from the manifest need to better account for the highly
prevalent subsyndromal presentations that, under DSM-IV-TR
classiﬁcation, do not meet the criteria for any of the 3 bipolar
diagnoses (Nusslock and Frank, 2011; Pacchiarotti et al., 2011b).
Moreover, the possibility of using the “with mixed features”
speciﬁer in MDD arises from studies showing that up to 40% of
MDEs have some degree of subthreshold bipolar features
(Nusslock and Frank, 2011), but poses the question of how to
deal with the bipolar–unipolar dichotomy, which was tradition-
ally based on the presence/absence of manic features.
The possibility of including fewer symptoms of the opposite
polarity in different groups (i.e., BD I, BD II, BD-NOS, and MDD)
is intimately linked to Kraepelin's concept that, instead of
mood categories (the unipolar–bipolar dichotomy), there is a
mood spectrum that varies from unipolar depression to pure
mania at its extremes (Akiskal et al., 2000; Angst et al., 2010;
Kraepelin, 1899; Perugi and Akiskal, 2005), thus recognizing
for the ﬁrst time the link between BD and MDD (Suppes, 2011).
This new classiﬁcation, however, will not help clarify the
boundaries between BD and related diagnoses (such as schi-
zoaffective disorder) (Murru et al., 2011) or resolve the
signiﬁcant overlap between unipolar and bipolar depression
that is known to lead to signiﬁcant rates of misdiagnosis
(Bschor et al., 2012; Matza et al., 2005; Moreno et al., 2012;
Nusslock and Frank, 2011; Thase, 2006; Zimmerman, 2010).
There will still be a distinction between mood disorder cate-
gories; an MDE associated with subthreshold bipolarity, for
instance, will still be considered an MDD and not in the bipolar
spectrum. The new classiﬁcation, though, will allow clinicians
and physicians to better assess and document subsyndromal
bipolarity in MDE, which should eventually help identify at-
risk MDD individuals and prevent the onset of threshold BD
(Nusslock and Frank, 2011), and minimize overdiagnosis ofBDNOS when there are only a few symptoms of the opposite
polarity.
3.2. Implications for treatment strategy
A change in the classiﬁcation system that takes into account
subthreshold bipolarity represents a challenge for clinicians,
researchers, and regulators, who may use it as a base for a
corresponding change in psychopharmacological choices. Treat-
ment guidelines do not usually recommend speciﬁc treatment for
mixed states; data on the appropriate pharmacological treatment
options is limited to subanalyses or post hoc analyses of studies
that have included patients with both manic and mixed episodes
(Fountoulakis et al., 2012; McIntyre and Yoon, 2012). As a
consequence, the selection of medication is usually based on
individual factors and short and long-term safety and tolerability.
It is largely recognized, however, that mixed manic/depressive
presentations in BD have a poorer pharmacological response
compared with pure episodes (Benazzi, 2008; Cassidy et al.,
2008; Gonzalez-Pinto et al., 2011), and combination therapy is
often required (Gonzalez-Pinto et al., 2007). In their meta-
analysis, Yildiz et al. (2011) found that mixed features predicted
poorer response to both active treatment and placebo. An addi-
tional challenge in the treatment of mixed states arises from the
mood-switching risk derived from the need to concurrently treat
both manic and depressive symptoms; an antipsychotic mono-
therapy centered on improving only manic symptoms can
increase the risk of switching to depression (Goikolea et al.,
2013; Vieta, 2005), particularly in the case of conventional
antipsychotics and drugs with a high polarity index (Popovic
et al., 2012). Conversely, antidepressant treatment to treat only
depressive symptoms can induce a manic switch (Baldessarini
et al., 2012; Fornaro et al., 2012; Pacchiarotti et al., 2011a; Valenti
et al., 2011). The drugs that showed positive effects in the subset
of patients with mixed mania as deﬁned in DSM-IV in placebo-
controlled trials (asenapine, olanzapine, and valproate) (Azorin
et al., 2013; Baker et al., 2003; Nivoli et al., 2012; Swann et al.,
1997; Yatham et al., 2013), and to some extent those that showed
separation from placebo in pooled analysis (aripiprazole and
ziprasidone) (Stahl et al., 2010; Suppes et al., 2008), may be the
best candidates for the treatment of the newly deﬁned DSM-5
mixed states. Of note, there are very few data on the use of
quetiapine in acute mixed states but positive adjunctive long-
term data (Vieta et al., 2012), and ziprasidone (Patkar et al., 2012)
has been tested in depressive mixed states (which did not exist in
the DSM-IV). Given that asenapine and olanzapine have also
positive data in combination with valproate, patients with mixed
mania who may not do well on monotherapy may be treated with
the combination of asenapine or olanzapine plus valproate.
Clinicians will face particular challenges for the treatment of
depressive mixed states because prospective and retrospective
analyses have shown that patients with MDD and a past history
of manic or hypomanic symptoms often progress from unipolar
major depression to BD (Angst et al., 2010; Cassano et al., 2004;
Fiedorowicz et al., 2011; Zimmermann et al., 2009). There is
evidence that the subgroup of patients with MDD who exhibit
bipolarity are more frequently resistant to treatment
(Rybakowski, 2012; Strakowski et al., 2011). Guidelines recom-
mend mood stabilizers, atypical antipsychotics, and antidepres-
sants (Fountoulakis et al., 2012), but there is controversy
regarding whether antipsychotic medications and mood stabili-
zers would be more appropriate than antidepressant monother-
apy in MDEs (Pae et al., 2012) because antidepressants have been
described to precipitate hypomanic episodes in both BD and MDD
(Baldessarini et al., 2012; Fornaro et al., 2012; Nusslock and
Frank, 2011; Pacchiarotti et al., 2011a; Strakowski et al., 2011;
Table 1
Description of the old (DSM-IV-TR) and new (DSM-5) classiﬁcation criteria for mood episodes.
DSM-IV-TR
mood episode
classiﬁcation
DSM-IV-TR criteria New DSM-5
mood
episode
classiﬁcation
DSM-5 Criteria for an episode
“with mixed features” speciﬁer
Applicability
of “mixed
features”
speciﬁer
Manic A distinct period of abnormally and persistently elevated,
expansive, or irritable mood, lasting at least 1 week. During
the period of mood disturbance, three (or more) of the
following symptoms have persisted and have been present
to a signiﬁcant degree:
• Inﬂated self-esteem or grandiosity.
• Decreased need for sleep.
• More talkative than usual or pressure to keep talking.
• Flight of ideas or subjective experience that thoughts
are racing.
• Distractibility.
• Increase in goal-directed activity or psychomotor
agitation.
• Excessive involvement in pleasurable activities that
have a high potential for painful consequences.
Manic Full criteria for a manic episode and at least 3 of the
following symptoms present:
• Prominent dysphoria or depressed mood as
indicated by either subjective report (e.g., feels sad
or empty) or observation made by others (e.g.,
appears tearful).
• Diminished interest or pleasure in all, or almost all,
activities, (as indicated by either subjective account
or observation made by others).
• Psychomotor retardation nearly every day
(observable by others, not merely subjective feelings
of being slowed down).
• Fatigue or loss of energy.
• Feelings of worthlessness or excessive or
inappropriate guilt (not merely self-reproach or guilt
about being sick).
• Recurrent thoughts of death (not just fear of dying),
recurrent suicidal ideation without a speciﬁc plan, or
a suicide attempt or a speciﬁc plan for committing.
Manic
episodes in
BD I
Major Depressive Five (or more) of the following symptoms have been
present during the same 2-week period and represent a
change from previous functioning; at least one of the
symptoms is either (1) depressed mood or (2) loss of
interest or pleasure.
• Depressed mood most of the day, nearly every day, as
indicated by either subjective report or observation
made by others
• Markedly diminished interest or pleasure in all, or
almost all, activities most of the day, nearly every day
• Signiﬁcant weight loss when not dieting or weight
gain, or decrease or increase in appetite nearly
every day
• Insomnia or hypersomnia nearly every day
• Psychomotor agitation or retardation nearly every day
• Fatigue or loss of energy nearly every day
• Feelings of worthlessness or excessive or inappropriate
guilt nearly every day
• Diminished ability to think or concentrate, or
indecisiveness, nearly every day
• Recurrent thoughts of death, recurrent suicidal
thoughts or intent
Major
Depressive
Full criteria for a major depressive episode and at least
3 of the following symptoms present:
• Elevated, expansive mood
• Inﬂated self-esteem or grandiosity
• More talkative than usual or pressure to keep talking
• Flight of ideas or subjective experience that thoughts
are racing
• Increase in energy or goal directed activity (either
socially, at work or school, or sexually)
• Increased or excessive involvement in activities that
have a high potential for painful consequences (e.g.,
engaging in unrestrained buying sprees, sexual
indiscretions, or foolish business investments)
• Decreased need for sleep (feeling rested despite
sleeping less than usual (to be contrasted from
insomnia)
MDE in BD I,
BD II, BDNOS
and MDD
Mixed The criteria are met both for a Manic episode and for a
Major Depressive episode (except for the duration) nearly
every day during at least 1-week period.
Manic with
mixed
features
For those who meet full episode criteria for both mania
and depression simultaneously, they should be labeled
as having a manic episode, with mixed features, because
of the marked impairment and clinical severity of full
mania.
Hypomanic A distinct period of persistently elevated, expansive, or
irritable mood, lasting throughout at least 4 days, that is
clearly different from the usual non-depressed mood
• Inﬂated self-esteem or grandiosity.
• Decreased need for sleep.
• More talkative than usual or pressure to keep talking.
• Flight of ideas or subjective experience that thoughts
are racing.
• Distractibility.
• Increase in goal-directed activity or psychomotor
agitation.
• Excessive involvement in pleasurable activities that
have a high potential for painful consequences.
Hypomanic Full criteria for hypomanic episode and at least 3 of the
same symptoms speciﬁed for manic with mixed features
• Prominent dysphoria or depressed mood as
indicated by either subjective report (e.g., feels sad
or empty) or observation made by others (e.g.,
appears tearful).
• Diminished interest or pleasure in all, or almost all,
activities, (as indicated by either subjective account
or observation made by others).
• Psychomotor retardation nearly every day
(observable by others, not merely subjective feelings
of being slowed down).
• Fatigue or loss of energy.
• Feelings of worthlessness or excessive or
inappropriate guilt (not merely self-reproach or guilt
about being sick).
• Recurrent thoughts of death (not just fear of dying),
recurrent suicidal ideation without a speciﬁc plan, or
a suicide attempt or a speciﬁc plan for committing.
Hypomanic
episodes in
BD I and BD II
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pressants as adjunctive therapy in BD patients with mixed
features, despite the lack of evidence to support that practice
(Rosa et al., 2010) However, further adding to the confusion, a
recent study, which retrospectively examined the predictive
validity of the proposed DSM-5 mixed criteria for MDD in a
community-based cohort, found that the presence of ≥2 mixed
symptoms was associated with better antidepressant treatment
outcomes (Perlis et al., 2012). A potential explanation for this
strange ﬁnding is that some bipolar features, while not being
particularly associated with antidepressant response, may actu-
ally be associated with a phenotype of MDD with greater
biological load as compared with other MDD phenotypes, in
which psychosocial aspects and adversity may play a major role,
and which may be less responsive to pharmacotherapy.
With the emergence of second-generation antipsychotics,
which in some cases have both antimanic and antidepressant
effects (Fountoulakis et al., 2012; McIntyre and Yoon, 2012),
monotherapy options in the treatment of mixed states may
increase. However, assessing their comparative effectiveness in
the treatment of the newly deﬁned mixed states will require
speciﬁc and prospectively designed clinical trials.3.3. Implications for research
Although it's predicted that in the short term the change in
deﬁnitions will slow progress and make it more difﬁcult to
translate research ﬁndings into clinical practice (Frances, 2009),
the inclusion of the “with mixed features” speciﬁer may have both
beneﬁts and disadvantages in several aspects of research over the
longer term. One expected result of the new classiﬁcation is that,
at the epidemiologic level, the lifetime prevalence of the bipolar
spectrum will change because a revision of the deﬁnition of
caseness may trigger a change in the reported rates of a disorder
(Regier et al., 1998). For instance, using the “with mixed features”
speciﬁer may increase the prevalence of manic, hypomanic, or
depressive episodes while decreasing the prevalence of BD-NOS,
which would indicated that prevalence based on the strict deﬁni-
tion of mixed states in DSM-IV-TR is unrealistic.
Another immediate major challenge will be how to compare
the clinical and epidemiologic data obtained when applying the
new classiﬁcation criteria to the existing data on mixed states. A
lot of existing data on the study of mixed states, including
epidemiology, morbidity, response to treatment, illness course,
or outcome, has come from studies that have applied broader and
more dimensionally oriented diagnostic classiﬁcations rather than
the strict DSM-IV-TR deﬁnition. Thus, the huge amount of preex-
isting information from randomized controlled trials or naturalis-
tic studies could be used for post hoc subanalyses using the new
mixed deﬁnitions to ascertain the validity and clinical utility of
this new classiﬁcation. One example is the above-mentioned study
on the validity of the DSM-5 mixed features criteria for MDD
(Perlis et al., 2012), in which the unexpected results suggest that
the mixed features criteria as newly operationalized in the DSM-
5DSM-5 will require additional, speciﬁcally designed studies.
Moreover, it will remain to be seen whether manic/hypomanic/
or depressive episodes with mixed features represent homoge-
neous groups with enough differentiation between them to facil-
itate the identiﬁcation of neurobiological, neurocognitive, or
neuroimaging correlates. This would be in line with the use of
clinically relevant biomarkers for personalized medicine, but if the
syndromes are not clearly distinguishable due owing to signiﬁcant
overlaps in criteria, such as in the case of unipolar–bipolar
depression, it will result in nonspeciﬁc ﬁndings, which will have
consequences not only for diagnosis, but also for treatment.Another concern that has arisen with the inclusion of sub-
threshold syndromes in DSM-5 is the fact that clinical trials,
through the inclusion of milder cases, may potentially include
false-positive patients, which would favor placebo responses of
less severe cases, eventually leading to a decrease in statistical
power (Butlen-Ducuing et al., 2012). However, as mentioned
above, the presence of mixed features actually decreased both
drug and placebo response, resulting in no detrimental effects on
signal detection (Yildiz et al., 2011). One possible drawback is that
the heterogeneity within diagnoses may increase, and actually
result in a gradation of severity (e.g., manic episodes with 3–6
depressive symptoms, or depressive episodes with 3–7 manic
symptoms) that will complicate the interpretation of clinical
outcomes. In spite of that, it will be informative and extremely
useful for clinical decision making to establish how these pre-
speciﬁed symptoms of the opposite polarity (as a quantitative
measure) affect the course of the illness, as well as the acute and
long-term treatment response. Ideally, those stratiﬁed analyses
will help make a more precise diagnosis that can predict, for
instance, the risk of a switch between mood disorder categories, or
the severity level at which a treatment choice is safe and effective.
In a diametrically opposite situation, this approach could yield
results in line with a continuum of symptoms that do not support
the existence of distinguishable categories, and simply add confu-
sion about treatment indications. However, dimensional assess-
ment is generally more beneﬁcial for research than for clinical
practice because researchers can use statistical instruments to deal
with quantitative data, whereas clinicians tend to assess patients
in a qualitative way. For example, the separation between MDD
with and without mixed features might help distinguish patients
who would respond to adjunctive antipsychotics from those who
would not.
3.4. Implications for education
The DSM is a primary clinical tool for making a diagnosis that is
taught to psychiatry residents, trainees in psychology, general
practitioners, and psychiatric nurses. The complex and heteroge-
neous clinical presentation of mixed states will force clinicians to
become familiar with the proposed deﬁnitions because they will
need to recognize the possible presence of opposite mood symp-
toms (e.g., dysphoria in manic or hypomanic episodes, or expan-
sive mood in MDE). Thus, this substantial change in classiﬁcation
criteria will require systems to measure mixed states and educa-
tors to teach how to implement them through tutorials, confer-
ences, continuing education materials, specialized journals, or
dedicated courses. The current situation, though, in which the
reliability of the diagnosis of BD is much higher than that of MDD
as deﬁned in DSM-5, suggests that adding a “with mixed features”
speciﬁer may not actually have a negative impact on diagnostic
skills (Freedman et al., 2013).
3.5. Implications for marketing authorization and harmonization
with other classiﬁcation systems
International regulatory agencies (e.g. Food and Drug Admin-
istration [FDA] and European Medicines Agency [EMA]) deﬁne
their therapeutic indications based on diagnostic categories in
DSM-IV-TR or ICD-10. Currently, the FDA licenses drugs for the
treatment of either manic or mixed episodes, whereas the EMA
only authorizes treatment for mixed episodes if supported by
speciﬁc studies. The new classiﬁcation will require that regulatory
agencies review their indications and approval policies for market-
ing authorization of drugs for BD and MDD, which may eventually
involve the need to perform additional clinical trials, particularly
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given compound.
With the advent of the DSM-5 revision, the World Health
Organization formed a DSM-ICD Harmonization Coordinating
Group to revise the ICD-10, to be published in 2015 (World
Health Organization, 2011), and harmonize the diagnostic criteria
between both classiﬁcation systems (World Health Organization,
2008). The need for an integration of DSM-5 and ICD-11 has been
discussed before (First, 2009; Jablensky, 2009; Moller, 2009), but it
seems to have become crucial in view of the trend toward mixed
dimensional–categorical classiﬁcation criteria implemented in
DSM-5. In the particular case of mixed states, it has been proposed
that ICD-11 should maintain the current (different diagnosis) for
mixed states, with some changes to account for ≥3 symptoms of
the opposite polarity, and with different subtypes based on the
presence or absence of psychotic symptoms (Ostergaard et al.,
2012). Although similar to the DSM-5 classiﬁcation, the proposal to
maintain mixed states in one classiﬁcation system that does not
exist in the other one would perpetuate the DSM/ICD divergence
and have consequences not only in epidemiology, but also in
research, regulatory issues, and treatment choices.
4. Alternative classiﬁcations based on other dimensions
or symptoms’ clusters
The rigidity of existing classiﬁcation systems has triggered
researchers to look for alternative pure dimensional perspectives,
which are based on the assumption that homogeneous clusters of
signs and symptoms (factors or core dimensions) correlate with
mood states and underlying categorical deﬁnitions. This is impor-
tant at both the nosological and psychopathological levels. The
symptom structure may also point to the most effective psycho-
pharmacological intervention and could help predict outcome if
related to treatment response. Several dimensions and symptom
clusters have been proposed to classify bipolar disorders, including
predominant polarity; lifetime psychotic symptoms; emotional
reactivity; cognitive impairment; or the cluster of impulsivity,
suicidality, and substance misuse (Henry and Etain, 2010). In the
particular case of mixed episodes, dimensional approaches have
been mainly explored in mixed manic states, mixed hypomania
has received less attention, and mixed depression has been usually
studied in the context of a full spectrum of mood disorders, thus
including unipolar depression (Swann et al., 2013b).
The factors or core dimensions that have been identiﬁed vary
among studies depending on the rating scales used to assess
symptoms. Common to mixed mania are anxiety, ≥1 depressive
component, irritability/hostility, and one component of psychosis, as
well as the classic elevation of mood and psychomotor activation
symptoms of mania (Swann et al., 2013a, 2013b). For mixed depres-
sion, agitated depression, or both, the identiﬁed factors of the mixed
component include irritability/aggressiveness, ﬂights of ideas/racing
thoughts, psychomotor agitation, increased talkativeness, and dis-
tractibility (Swann et al., 2013a). Since DSM-III, psychomotor agitation
has been included as a subcriterion for the diagnosis of both manic
episodes and MDE, and thus considered an overlapping affective
symptom that has resulted in its exclusion, together with irritability
and distractibility, as a criterion for an MDE with mixed features in
the new DSM-5 proposal (Table 1). Under this assumption, an MDE
may be associated with psychomotor activation or inhibition, when
clinical observations and factor analyses have shown that activation
and irritability may represent characteristic symptoms of mixed
depressive states (Perugi and Akiskal, 2005; Swann et al., 2013b).
One factor analysis has been performed on the full spectrum of
mood subtype states: pure depression, mixed depression, full
mixed states (DSM-IV-TR deﬁnition), manic mixed states, and pure
mania (Bertschy et al., 2007). This study identiﬁed a dysphoricdimension independent to the classic manic and depressive
symptoms that included the 3 classic symptoms of dysphoria:
inner tension, impulsivity, and irritability. The dysphoria score
differed between the different mood categories, and thus it was
proposed that this dysphoric dimension was associated with
mixed states in particular, although they were not able to distin-
guish them, at the statistical level, from pure syndromic states
(Bertschy et al., 2007). Another recent factor analysis of manic,
depressive, and mixed episodes in BD I inpatients identiﬁed a
speciﬁc mixed factor dimension that the authors termed “mixi-
city,” which distinguishes mixed episodes from pure manic and
depressive episodes (Pacchiarotti et al., 2013). This dimension
includes the items anxiety, tension, suicidality, motor hyperactiv-
ity, and excitement; is unrelated to depressed mood; and does not
include psychomotor retardation. This “mixicity” dimension was
found to be associated with predominant depressive polarity,
more lifetime mixed episodes, worse course of illness, and a
higher frequency of previous antidepressant use. Moreover, the
“mixicity” factor was associated with an anxious temperament
and a premorbid temperament mainly characterized by anxiety
and tension (Pacchiarotti et al., 2013). This dimensional pattern of
an anxious–excited arousal is not in agreement with some of the
symptoms needed to deﬁne a manic episode with mixed features
in DSM-5. Dysphoria is included, but psychomotor retardation is
also a possible symptom, and anxiety is not explicitly included in
the DSM-5 deﬁnition.
Another study on mood episodes, in the context of BD only,
deﬁned a mixed-state index, the product of Z-transformed depres-
sion and mania scores, to quantify how strongly mixed the episode
is (Swann et al., 2009). This index was found to be elevated in
predominantly manic or depressive mixed states, and to be
positively correlated with anxiety and psychosis (Swann et al.,
2009), and therefore provides an indication of the strength of the
mixed component. Moreover, the study showed that mixed states
were associated with symptoms of hyperactivity and negative
cognitions, but not with subjective depressive or elevated mood
(Swann et al., 2009). One dimensional approach, which has been
used to study how mixed states differ from pure syndromal states,
is based on emotional reactivity, deﬁned as a subscore of beha-
vioral activation or inhibition (Henry et al., 2007). Emotional
reactivity in patients with BD, assessed with a scale with 5 quanti-
tative dimensions that explore excitatory and inhibition processes
(Henry et al., 2008), identiﬁed a “mixed cluster” characterized by
emotional hyperreactivity (Henry et al., 2007). The cluster was
composed of patients with DSM-IV diagnosis of MDE, mixed
episode, or hypomanic episode, thus classifying mood episodes
as a continuum ranging from inhibition to activation (Henry et al.,
2007). Moreover, although MDE without manic symptoms was
characterized by overall behavioral inhibition and emotional
hyporeactivity, MDE with manic symptoms was more likely to
be associated with mild activation and hyperreactivity, with scores
similar to those of manic and mixed states as deﬁned by DSM-IV
(Henry et al., 2010). This approach can also be used to describe and
predict symptom trajectories (M'Bailara et al., 2013).
In summary, pure dimensional approaches, as opposed to
combined or categorical deﬁnitions of mixed states, may help
identify homogeneous groups of patients and potentially impact
treatment choices. However, the different patterns of response to
existing therapeutic agents by the different subgroups identiﬁed
will require further investigations and treatment trials.5. Conclusions
The existence of mixed features in mood episodes requires
special attention because of their high prevalence and clinical
E. Vieta, ]*>M. Valentí / Journal of Affective Disorders 148 (2013) 28–3634characteristics (in particular increased severity), worse response to
treatment, and a longer-term course, as compared with pure
syndromic episodes. The nosological deﬁnition of mixed features
is crucial for a reliable and valid diagnosis that enhances clinical
decision making. The classiﬁcation of mixed states as deﬁned in
DSM-5 will allow the inclusion of subthreshold symptomatology of
the opposite polarity and will be less restrictive than previous
versions of the DSM, although it will necessarily challenge clin-
icians and researchers at the treatment, educational, or methodo-
logical levels. The speciﬁcity and sensitivity of this diagnostic
construct and the treatment implications will need to be assessed
by new and additional empirical studies.Role of funding source
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